Does the New Formulation of OxyContin® Deter Misuse? A Qualitative Analysis

REFERENCES

• Anglin, M. K., & White, J. C. (1999). Poverty, health care, and problems of prescription medication: a case study. Substance Use Misuse, 34(14), 2073–2093.
   PubMed Web of Science ®Google Scholar
• Appalachian Regional Commission. (2011). County Economic Status and Number of Distressed Areas in Appalachian Kentucky, Fiscal Year 2012. Retrieved from http://www.arc.gov/ images/appregion/ economic_statusFY2012/CountyEconomic StatusndDistressAreasFY2012Kentucky.pdf
   Google Scholar
• Barendregt, C., van der Poel, A., & van de Mheen, D. (2005). Tracing selection effects in three non- probability samples. European Addiction Research, 11(3), 124–131.
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., Inciardi, J. A., & Muñoz, A. (2005). Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. Journal of Pain, 6(10), 662–672.
   PubMed Web of Science ®Google Scholar
• Davis, M. P., Varga, J., Dickerson, D., Walsh, D., LeGrand, S. B., & Lagman, R. (2003). Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Supportive Care in Cancer, 11(2), 84–92.
   PubMed Web of Science ®Google Scholar
• Dew, B., Elifson, K., & Dozier, M. (2007). Social and environmental factors and their influence on drug use vulnerability and resiliency in rural populations. Journal of Rural Health, 23(S1), 16–21.
   PubMed Web of Science ®Google Scholar
• Havens, J. R., Oser, C. B., Leukefeld, C. G., Webster, J. M., Martin, S. S., O'Connell, D. J., (2007a). Differences in prevalence of prescription opiate misuse among rural and urban probationers. American Journal of Drug and Alcohol Abuse, 33(2), 309–317.
   PubMed Web of Science ®Google Scholar
• Havens, J. R., Walker, R., & Leukefeld, C. G. (2007b). Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug and Alcohol Dependence, 87(1), 98–102.
   PubMed Web of Science ®Google Scholar
• Havens, J. R., Walker, R., & Leukefeld, C. G. (2008). Prescription opioid use in rural Appalachia: A community based study. Journal of Opioid Management, 4(2), 63–71.
   PubMedGoogle Scholar
• Inciardi, J. A., & Goode, J. L. (2003). Miracle medicine or problem drug? OxyContin and prescription drug abuse. Consumer Research, July 2003, 17–21.
   Google Scholar
• Jonas, A. B., Young, A. M., Oser, C. B., Leukefeld, C. G., & Havens, J. R. (2012). OxyContin as currency: OxyContin use and increased social capital among rural Appalachian drug users. Social Science and Medicine, 74(10), 1602–1609.
   PubMed Web of Science ®Google Scholar
• Kokkevi, A., Richardson, C., Palermou, B., & Leventakou, V. (1997). Reliability of drug dependents’ self-reports. Drug and Alcohol Dependence, 45(1–2), 55–61.
   PubMed Web of Science ®Google Scholar
• Latkin, C. A., Vlahov, D., & Anthony, J. C. (1993). Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction, 88(4), 517–526.
   PubMed Web of Science ®Google Scholar
• Lipman, A. G. (2003). What have we learned from OxyContin? Journal of Pain and Palliative Care Pharmacotherapy, 17(1), 1–4.
   Google Scholar
• Muhr, T. (2010). ATLAS.ti. Berlin: Scientific Software Development.
   Google Scholar
• Passik, S. D. (2003). Same as it ever was? Life after the OxyContin® media frenzy. Journal of Pain and Symptom Management, 25(3), 199–201.
   PubMed Web of Science ®Google Scholar
• Purdue Pharma L. P. (2010). Statement of Purdue Pharma L. P. Regarding FDA's Approval of Reformulated OxyContin® (Oxycodone HCl Controlled-Release) Tablets. Retrieved from http://www.purduepharma.com/News-and-Media/News/Pages/ 20100405.aspx
   Google Scholar
• Quintero, G., Peterson, J., & Young, B. (2006). An exploratory study of socio-cultural factors contributing to prescription drug misuse among college students. Journal of Drug Issues, 36(4), 903–932.
   Web of Science ®Google Scholar
• Reiger, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264(19), 2511–2518.
   PubMed Web of Science ®Google Scholar
• Rosenblum, A., Parrino, M., Schnoll, S. H., Fong, C., Maxwell, C., Cleland, C. M., (2007). Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and Alcohol Dependence, 90(1), 64–71.
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. United States Census 2000. Washington, DC: U.S. Census Bureau.
   Google Scholar
• U.S. General Accounting Office. (2003). Prescription drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. Washington, DC: U.S. General Accounting Office.
   Google Scholar
• U.S. National Drug Intelligence Center. (2004). Intelligence Bulletin: OxyContin Diversion, Availability, and Abuse. Johnstown, PA: U.S. National Drug Intelligence Center.
   Google Scholar
• U.S. National Drug Intelligence Center. (2010). Appalachia High Intensity Drug Trafficking Area: Drug Market Analysis 2010. Johnstown, PA: U.S. National Drug Intelligence Center.
   Google Scholar
• U.S. Office of National Drug Control Policy. (2011). Epidemic: Responding to America's Prescription Drug Abuse Crisis. Washington, DC: U.S. Office of National Drug Control Policy.
   Google Scholar
• U.S. Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: U.S. Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Van Zee, A. (2009). The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. American Journal of Public Health, 99(2), 221–227.
   PubMed Web of Science ®Google Scholar
• Webster, L. R., & Fine, P. G. (2010). Approaches to improve pain relief while minimizing opioid abuse liability. Journal of Pain, 11(7), 602–211.
   PubMed Web of Science ®Google Scholar
• Wolfe, S. (2010). Annual U.S. OxyContin prescriptions (millions). U.S. Food and Drug Administration. Retrieved from http:// www.fda.gov/downloads/AdvisoryCommittees/Committees Meeting Materials/Drugs /AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM220954.pdf
   Google Scholar
• Young, A. M., & Havens, J. R. (2012). Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: A cross-sectional comparison and retrospective survival analysis. Addiction, 107(3), 587–596.
   PubMed Web of Science ®Google Scholar